Turn Therapeutics Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
TTRX Nasdaq 2830 turntherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Turn Therapeutics Inc.

Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis - Jun 1st, 2026 6:30 am
Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model - May 27th, 2026 6:05 am
Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026 - May 19th, 2026 6:01 am
Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead - May 18th, 2026 6:05 am
Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates - May 11th, 2026 2:05 pm
Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates - Mar 31st, 2026 2:05 pm
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group - Mar 24th, 2026 6:00 am
Turn Therapeutics Talks GX-03 Phase II Eczema Data Timeline and Non-Systemic Topical Strategy - Mar 1st, 2026 11:08 pm
Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs - Feb 17th, 2026 6:00 am
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences - Feb 9th, 2026 6:00 am
Positive Signs As Multiple Insiders Buy Turn Therapeutics Stock - Feb 4th, 2026 6:17 am
Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference - Jan 12th, 2026 6:05 am
Great week for Turn Therapeutics Inc. (NASDAQ:TTRX) insiders who have 59% stake and they haven’t stopped buying - Jan 8th, 2026 5:13 am
Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors - Jan 7th, 2026 2:05 pm
Here Are Monday’s Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More - Dec 29th, 2025 5:52 am
Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates - Nov 13th, 2025 6:00 am
Turn Therapeutics CEO, Bradley Burnam, Speaks with Former Director of the Centers for Disease Control and Prevention Dr. Robert Redfield, M.D. - Nov 11th, 2025 2:05 pm
Turn Therapeutics’ GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine - Nov 11th, 2025 6:00 am
Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications - Nov 4th, 2025 3:07 pm
Turn Therapeutics Enters Global Supply, Development, and License Agreement with Leading Medical-Surgical Product Manufacturer and Distributor Medline - Oct 30th, 2025 5:30 am